Simultaneous Portal and Hepatic Vein Embolization Versus Portal Vein Embolization for Hypertrophy of the Future Liver Remnant Before Major Hepatectomy of Non-cirrhotic Liver : a Multicentric Comparative Randomized Phase II Trial
The hypothesis is that liver venous deprivation (LVD) could strongly improve hypertrophy of the future remnant liver (FRL) at 3 weeks, as compared to portal vein embolization (PVE) in patient with liver metastases from colo-rectal origin considered as resectable.
• Liver metastases from colo-rectal origin considered as resectable (as validated by a multidisciplinary committee with at least one senior hepatic surgeon) provided sufficient FRL volume
• Percentage of FRL volume \< 30%
• Age ≥ 18 years
• General health status World Health Organisation 0,1
• Estimated life expectancy \> 3 months
• Patients whose biological parameters are :
‣ Platelets ≥100,000/mm3,
⁃ Polynuclear neutrophils ≥ 1000/mm3,
⁃ Hemoglobin≥ 9g/dL (even transfused patients can be included)
⁃ Creatininemia \< 1.5 times the normal value
⁃ Creatinine clearance \> 30 milliliters (mL)/min
⁃ Bilirubinemia ≤ 1,5 times the normal value
⁃ liver transaminases ≤ 5 times the normal value
⁃ prothrombin rate \> 70%
• Reference liver CT-Scan or MRI done during the 30 days preceding PVE or LVD.
• Written informed consent
• National health insurance cover